Rapid Micro Biosystems Raises $81M to Continue Global Expansion of Automated Pharmaceutical QC Platform to Improve Data Integrity and Safety in Biologics, Vaccines, and Cell & Gene Therapy Manufacturing

Rapid Micro Biosystems融资8100万美元,继续在全球扩展自动化制药QC平台,以提高生物制品、疫苗和细胞及基因治疗制造中的数据完整性和安全性

2021-03-17 01:00:09 BioSpace

本文共1762个字,阅读需5分钟

LOWELL, Mass., March 16, 2021 -- Rapid Micro Biosystems, Inc., the leading provider of data integrity and automation technology for microbial detection in biopharmaceutical manufacturing, today announced the completion of an $81 million equity financing. The funding round was led by new investor D1 Capital Partners, along with funds and accounts managed by BlackRock, funds and accounts advised by T. Rowe Price Associates, Inc., Adage Capital Management, Sunley House Capital Management, and CaaS Capital Management. These new investors join an existing investor group that includes Bain Capital Life Sciences, Ally Bridge Group, Longitude Capital, Xeraya Capital, Endeavour Vision, Quaker Partners, and Asahi Kasei Medical. Including this latest financing, Rapid Micro Biosystems has raised over $340 million of equity to fuel its expansion. A majority of the global top-20 pharmaceutical companies use Rapid Micro Biosystem’s Growth Direct® System to automate their critical compendial microbial testing processes. The Growth Direct® System enables pharmaceutical companies to ensure robust data integrity and regulatory compliance, meaningfully decrease errors, and significantly increase efficiency of their global supply chains, thereby reducing the risk of catastrophic contamination events and product recalls. Rapid Micro Biosystems has seen accelerating adoption of the Growth Direct® System by leading biopharmaceutical companies to expand drug and vaccine production by meeting stringent quality requirements and maximizing capacity in response to growing global demand. “This new investment will enable continued acceleration of our company’s growth as we help global drug manufacturers significantly improve data integrity, reduce risk, accelerate decision making and improve the operational efficiency of their quality control processes,” said Robert Spignesi, President and Chief Executive Officer of Rapid Micro Biosystems. “We are excited about the support of our new investors, who share our mission of improving the robustness and safety of the global pharmaceutical manufacturing ecosystem.” “We believe that Rapid Micro Biosystems is modernizing microbial quality control, bringing much needed data integrity and automation to a critical function in drug manufacturing,” said James Rogers, Analyst at D1 Capital Partners. “The company is exceptionally well-positioned to address the fast-emerging class of cell and gene therapies, a category of personalized medicines which are manufactured in small batches with extensive material handling under intensive microbial quality control. As significant numbers of these highly advanced therapeutics come to market, leading pharmaceutical companies will rely on Rapid Micro Biosystems to enable the complex processes necessary to ensure these products are safe for patients.” Rapid Micro Biosystems has seen significant global demand for its system as regulators push for more stringent quality and data integrity as volumes and manufacturing complexity of high-value drug production increase. The ongoing global health threat posed by infectious diseases, such as COVID-19, only serves to intensify the need for pharmaceutical companies and regulators to drive much needed investment in advanced technologies, such as those provided by Rapid Micro Biosystems. J.P. Morgan Securities LLC served as sole placement agent to Rapid Micro Biosystems in connection with the transaction. About Rapid Micro Biosystems Rapid Micro Biosystems is the industry leader in automated detection of microbial contamination with innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company’s Growth Direct® platform - the only growth-based platform to fully automate traditional microbial testing - detects contamination more quickly, delivering compelling economic benefits to manufacturers while improving their quality control (QC) process. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Germany and the Netherlands. For more information visit www.rapidmicrobio.com. Follow RMB at @rapidmicrobio or LinkedIn. About D1 Capital Partners D1 Capital Partners is a global investment firm that operates across public and private markets. The firm combines the talent and operational excellence of a large, premier asset management firm with the flexible mandate and long-term time horizon of a family office. Founded in 2018 by Daniel Sundheim, D1 focuses on investing in the global internet, technology, telecom, media, consumer, healthcare, financial, industrial, and real estate sectors. Contact for US and Global Media: media@rapidmicrobio.com
马萨诸塞州洛厄尔,2021年3月16日--生物制药制造中微生物检测的数据完整性和自动化技术的领先提供商Rapid MicroBiosystems公司今天宣布完成8100万美元的股权融资。 这轮融资由新投资者D1 Capital Partners牵头,还有贝莱德管理的基金和账户、T.Rowe Price Associates,Inc.、Adage Capital Management、Sunley House Capital Management和CaaS Capital Management提供咨询的基金和账户。这些新的投资者加入了一个现有的投资者集团,该集团包括贝恩资本生命科学公司、Ally Bridge group、Longitude Capital、Xeraya Capital、Endeavour Vision、Quaker Partners和Asahi Kasei Medical。 包括这次最新的融资在内,快速微生物系统公司已经筹集了超过3.4亿美元的股本来推动其扩张。 全球排名前20位的大多数制药公司都使用快速微生物系统公司的直接®系统来自动化其关键的简明微生物检测过程。Growth Direct®系统使制药公司能够确保可靠的数据完整性和遵守法规,显著减少错误,并显著提高其全球供应链的效率,从而降低灾难性污染事件和产品召回的风险。 Rapid Micro Biosystems公司已经看到领先的生物制药公司加速采用增长直接®系统,通过满足严格的质量要求和最大限度地提高产能来扩大药物和疫苗生产,以应对不断增长的全球需求。 Rapid MicroBiosystems公司总裁兼首席执行官罗伯特·斯皮格内西说:“这项新的投资将使我们公司的增长继续加快,因为我们帮助全球药品制造商显著提高数据完整性、降低风险、加速决策并提高其质量控制过程的运作效率。“我们对我们新投资者的支持感到兴奋,他们与我们一样肩负着提高全球医药制造生态系统的稳健性和安全性的使命。” D1 Capital Partners的分析师詹姆斯·罗杰斯说:“我们相信快速微生物系统正在使微生物质量控制现代化,为药品制造的一个关键功能带来急需的数据完整性和自动化。”“该公司在处理迅速出现的细胞和基因疗法这类个性化药物方面处于特别有利的地位,这类药物是在严格的微生物质量控制下,通过大量的材料处理,以小批量生产的。随着这些高度先进的治疗药物的大量上市,领先的制药公司将依赖快速微型生物系统来实现必要的复杂过程,以确保这些产品对患者安全。“ 随着高价值药物产量的增加和制造复杂性的提高,监管机构要求更严格的质量和数据完整性,快速微生物系统公司在全球范围内对其系统需求巨大。COVID-19等传染病持续对全球健康构成威胁,这只会加剧制药公司和监管机构推动对先进技术(如快速微生物系统提供的技术)进行亟需的投资的必要性。 J.P.摩根证券有限责任公司担任与该交易有关的快速微型生物系统公司的唯一配售代理。 快速微型生物系统 Rapid MicroBiosystems是自动化检测微生物污染的行业领先者,其创新产品用于快速、准确和高效地检测药品、生物制品、生物技术产品、医疗器械和个人护理产品制造中的微生物污染。该公司的增长直接®平台--唯一一个完全自动化传统微生物检测的基于增长的平台--可以更快地检测污染,在改善其质量控制(QC)过程的同时为制造商带来令人信服的经济效益。该公司的总部设在马萨诸塞州的洛厄尔,并在美国设有生产基地,在德国和荷兰设有全球办事处。欲了解更多信息,请访问www.rapidmicrobio.com。在@rapidmicrobio或LinkedIn上关注RMB。 关于D1 Capital Partners D1 Capital Partners是一家全球性投资公司,在公共和私人市场开展业务。该公司结合了大型卓越资产管理公司的人才和卓越运营能力,以及家族办公室的灵活授权和长期业务。D1由Daniel Sundheim于2018年创立,专注于投资全球互联网、科技、电信、媒体、消费、医疗保健、金融、工业和房地产领域。 美国和全球媒体的联系方式: 电子邮件:media@rapidmicrobio.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文